Abbreviations & Acronyms ADT = androgen deprivation therapy BCRFS = biochemical recurrencefree survival ccRCC = clear cell renal cell carcinoma CRP = C-reactive protein CRPC = castration-resistant prostate cancer CSS = cancer-specific survival DFS = disease-free survival GPS = Glasgow Prognostic Score HR = hazard ratio IL = interleukin mCRPC = metastatic castrationresistant prostate cancer MFS = metastasis-free survival mGPS = modified Glasgow Prognostic Score MIBC = muscle-invasive bladder cancer MLR = monocyte-to-lymphocyte ratio MMT = molecular-targeted therapy mPC = metastatic prostate cancer NA = not accessed NLR = neutrophil-to-lymphocyte ratio NMIBC = non-muscle-invasive bladder cancer OR = odds ratio OS = overall survival papRCC = papillary renal cell carcinoma PC = prostate cancer PFS = progression-free survival PLR = platelet-to-lymphocyte ratio PNI = prognostic nutritional index post = post-treatment pre = pretreatment RCC = renal cell carcinoma RFS = recurrence-free survival RNU = radical nephroureterectomy SIR = systemic inflammatory response TURBT = transurethral resection bladder tumor UC = urothelial carcinoma UUT = upper urinary tract Abstract: The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C-reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C-reactive protein and albumin level; the neutrophil-to-lymphocyte ratio; the platelet-to-lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post-treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C-reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and prognostic nutritional index.
Introduction
Emerging evidence suggests that chronic inflammation plays an important role in the development and progression of most cancers. 1 Although inflammation is associated with cancer development in approximately 20% of cancer patients, bacteria-or virus-induced chronic inflammation does not commonly directly contribute to the development of urological cancer. However, infection, obesity, tobacco smoking and alcohol consumption, which are wellknown risk factors for many cancers, might be involved in cancer development through chronic inflammation. Among these risk factors, obesity is associated with the development of kidney and PCs.
2 A recent in vitro study regarding PC showed that obesity promotes macrophage infiltration into the prostate tumor microenvironment, inducing tumor-associated macrophage polarization through the COX-2/PGE2 pathway. 3 In contrast, cancer cells per se elicit inflammation by recruitment and activation of inflammatory cells in the tumor microenvironment. 4 In the urological cancer research field, several studies have shown an association among infiltration of inflammatory cells, such as neutrophils and macrophages, tumor aggressiveness, and poor prognosis. [5] [6] [7] Furthermore, Jensen et al. reported that the presence of intratumoral neutrophils is an independent prognostic factor for short recurrence-free, cancer-specific and OS in localized ccRCC. 8 In addition, Deryugina et al. reported that tissue-infiltrating neutrophils are a major source of angiogenesis-inducing MMP-9 in the tumor microenvironment in a model of PC. tumor microenvironment. 10 This inflammatory response is measured in the peripheral blood, and the SIR is associated with survival in patients with a variety of cancers. 11, 12 The SIR can be monitored using two categories of indices: concentration of specific serum proteins (albumin, CRP, fibrinogen) and a differential blood cell count (neutrophil, lymphocyte, monocyte, platelet). 13 Many researchers have investigated the prognostic value of these SIR markers in various types of cancer. [14] [15] [16] [17] Furthermore, combinations of these indices, such as the GPS, which consists of the serum CRP and albumin level; the NLR; the PLR; and the PNI, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research, including urological cancers. [18] [19] [20] [21] [22] [23] Most studies have evaluated the prognostic and predictive role of pretreatment SIR markers, although some have focused on the role of post-treatment SIR markers at specific points during the clinical course.
Recently, in addition to cytotoxic agents, molecular-targeted drugs and immune checkpoint inhibitors have been introduced as new treatment options in patients with urological cancers, such as metastatic RCC and metastatic UC. [24] [25] [26] The role of molecular markers in appropriate patient selection has also been investigated. 27 Even in such circumstances, there have been an increasing number of clinical studies evaluating the role of SIR markers in cancer patients. Therefore, the aim of the present review was to provide a concise overview regarding SIR markers in urological cancers, specifically CRP, GPS/mGPS, NLR, PLR and PNI.
Serum protein markers CRP
Serum CRP, one of the best known markers of SIR, reacts with the pneumococcal C-polysaccharide in the plasma of patients during the acute phase of pneumococcal pneumonia. 28 CRP is produced in hepatocytes, and the production is regulated by inflammation-associated cytokines, including IL-6 and IL-1b. IL-6 is produced in various cells, including inflammatory cells (T cells and macrophages), endothelial cells, fibroblasts and cancer cells. IL-1b is produced in various inflammatory cells, including macrophages, dendritic cells, T cells and B cells. 13, 29 Thus, serum CRP concentration might be elevated owing to hepatic CRP synthesis through stimulation by cancer cell-derived inflammatory cytokines. Elevation of CRP is associated with poorer survival in patients with cancer. 30, 31 Measurement of CRP is inexpensive, sensitive and reproducible. To date, there are hundreds of studies evaluating the prognostic role of CRP in patients with urological cancer. Therefore, I reviewed those articles published in the past decade that investigated the role of CRP in patients with RCC, UC and PC.
CRP in RCC
A summary of recent studies investigating the prognostic role of CRP level in RCC is shown in Table 1 . [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Four studies evaluated the pre-and post-treatment CRP value, and the remainder only evaluated the pretreatment value. The cut-off value for high versus low CRP level varied from 0.3 to 10 mg/dL, with most studies using a cut-off value of approximately 0.5 mg/dL. Similar cut-off values were selected whether the patients showed metastasis or not. All studies showed a significant association between high CRP and poor prognosis. Two studies by de Martino et al. and Komai et al. evaluated localized RCC patients who underwent radical nephrectomy. Both studies used a cut-off value of 0.5 mg/ dL. 46, 49 The proportion of patients with elevated CRP in these studies was relatively small compared with those in studies that evaluated metastatic RCC patients. Both studies showed that preoperative elevated CRP was an independent prognostic factor in localized RCC patients. Eight studies evaluated metastatic RCC patients who were treated with molecular-targeted agents. Of these, two studies investigated the prognostic role of a post-treatment change in CRP level. Yasuda et al. divided patients into three groups based on early CRP kinetics: non-elevated, patients whose baseline CRP levels were <1 mg/dL; early CRP responder, patients whose baseline CRP levels were ≥1 mg/dL and had decreased by >20% at 4 weeks after treatment; and non-early responder, the remaining patients. 32 The 1-year PFS rates of patients in the non-elevated, early CRP responder, and nonearly CRP responder groups were 50, 23, and 9.7%, respectively (P < 0.001). The non-early CRP group had a significantly poorer prognosis than did the non-elevated CRP group (HR 4.19, P < 0.001). Teishima et al. divided their cohort of metastatic RCC patients into three groups using a cut-off value of 0.5 mg/dL and post-treatment change in CRP: lower CRP, non-decreased higher CRP and decreased higher CRP groups (regardless of the range between pre-and post-treatment CRP value). 33 The decreased higher CRP group patients showed significantly better prognosis than did the nondecreased higher CRP group (HR 0.171, P = 0.0021). Although there was a prognostic value of CRP kinetics for these two groups, the findings should be interpreted with care because of the different cut-off values and the definition regarding the post-treatment decrease in CRP level.
CRP in UC
A summary of recent studies investigating the prognostic role of CRP level in UC is shown in Table 2 . [50] [51] [52] [53] [54] [55] The cut-off value for high versus low CRP level varied from 0.5 to 8 mg/dL. One study by Saito et al. evaluated the pre-and post-treatment CRP value. 54 They divided patients into three groups according to CRP kinetics based on baseline and nadir CRP levels. Patients whose baseline CRP levels were <5 mg/ L, patients whose baseline CRP levels were ≥5 mg/L and normalized (<5 mg/L), and patients whose baseline CRP levels were ≥5 mg/L and never normalized were assigned to non-elevated, normalized and non-normalized CRP groups, respectively. The patients in the non-normalized CRP group showed significantly poorer prognosis than did the patients in the non-elevated CRP group (HR 2.21, P = 0.001).
CRP in PC
A summary of recent studies investigating the prognostic role of CRP level in PC is shown in Table 3 . [56] [57] [58] [59] [60] [61] The cut-off value for high versus low CRP level varied from 0.1 to 0.5 mg/dL. One study examined patients treated with 3-D conformal radiotherapy, and the remaining studies examined mCRPC patients treated with medical treatment. All six studies showed that elevated CRP level is a predictor of poor prognosis.
GPS/mGPS
GPS, a measure based on the combination of serum CRP and albumin (Table 4) , was developed, found to have significant prognostic value in patients with advanced non-small cell lung cancer and subsequently refined to form the mGPS. 18, 19 GPS/mGPS is considered a measure of systemic inflammation, and reflects immune response and nutritional status in patients with various types of cancer. Many studies have shown the independent prognostic value of GPS/mGPS in cancer patients. 18, 19, 62 The main advantage of GPS/mGPS as a scoring system is that it uses a defined cut-off value. Therefore, it is easy to compare results of different studies evaluating the prognostic value of GPS/mGPS.
GPS/mGPS in RCC
A summary of six studies investigating the prognostic role of GPS/mGPS in RCC is shown in Table 5 . [63] [64] [65] [66] [67] [68] Three studies included only non-metastatic RCC patients. The proportion of patients with an elevated GPS/mGPS varied from 15.7 to 31%. In contrast, the proportion of metastatic RCC patients with an elevated GPS/mGPS was 67% and 72.3%. The study by Tsujino et al. included 195 non-metastatic patients and 24 metastatic patients; the proportion of elevated GPS/mGPS in these two groups was 24 of 195 (12.3%) and 11 of 24 (45.8%), respectively. 64 As expected, metastatic patients seemed to have an elevated GPS/mGPS than did non-metastatic cases. All studies showed a significant association between elevated GPS/mGPS and worse prognosis.
GPS/mGPS in UC
A summary of six studies investigating the prognostic role of GPS/mGPS in UC is shown in Table 6 . [69] [70] [71] [72] [73] [74] Four studies 71, 73 Four studies showed a prognostic value of GPS/mGPS in relation to OS or RFS: increased GPS/mGPS was significantly associated with worse prognosis. Lucca et al. evaluated the association between non-organ-confined disease and several SIR markers including NLR, PLR, MLR, PNI and GPS in patients who underwent radical cystectomy. They showed that GPS as well as T stage, lymphovascular invasion and abnormal imaging were independent predictors of non-organ-confined disease; they further developed a preoperative nomogram predicting non-organ-confined disease. Furthermore, Cho et al. analyzed the association of perioperative clinicopathological variables, including GPS and intravesical recurrence in patients who underwent RNU for upper tract UC. 73 They suggested that GPS as well as performance status, the presence of diabetes mellitus and cortical thinning are associated with intravesical recurrence after RNU. However, they did not show a significant association between GPS and OS. Further studies 
are required to validate the prognostic value of GPS/mGPS in patients with UC.
GPS/mGPS in PC
A few studies to date have reported the prognostic value of GPS/mGPS in PC. Shafique et al. analyzed data from the Scottish Cancer Registry and reported that patients with a higher mGPS had a significantly higher risk of death. 75 However, disease stage and type of treatment in the study cohort were clear. Linton et al. analyzed the prognostic role of mGPS and NLR in patients with metastatic castration-resistant cancer who received docetaxel and prednisone AE AT101 (AT-101-CS-205 trial). 76 They showed a significant association between mGPS and OS (HR 1.87, P < 0.001; median survival 23.5 months at mGPS 0 vs 9.8 months at mGPS 2). Further studies are required to validate the prognostic value of GPS/mGPS in patients with PC.
Differential blood cell markers NLR
The NLR is the absolute neutrophil count divided by the absolute lymphocyte count; NLR was first reported as a parameter of systemic inflammation and stress in critically ill patients. 77 Since then, many research groups have reported that increased NLR is associated with poor survival in patients with various types of cancer, such as colorectal, ovarian and gastric cancer. [78] [79] [80] It is an inexpensive and easily acquired marker that can be used after a routine preoperative blood examination. In the urological cancer field, our group first showed the prognostic value of preoperative NLR in patients with non-metastatic RCC. 81 To date, there have been a large number of studies regarding the prognostic value of NLR in urological cancer, including RCC, UC and PC. 76, [82] [83] [84] [85] [86] [87] [88] In addition, several meta-analyses showed that increased NLR is associated with worse outcome. 51, [89] [90] [91] NLR in RCC A summary of 18 recent studies investigating the prognostic role of NLR in RCC is shown in Table 7 . 43, 63, [81] [82] [83] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] A total of 10 studies included mainly metastatic patients; in eight studies, the main treatment was molecular-targeted agents; and in two studies, the treatment was cytoreductive nephrectomy. Two studies evaluated the prognostic value of NLR using continuous values, and the remaining studies used dichotomized NLR values. Three studies evaluated pre-and post-treatment NLR, and the remaining studies evaluated the pretreatment value only. The cut-off value for high versus low NLR varied from 2.2 to 4. The cut-off value of NLR is not always higher in studies of patients with metastatic disease than in those of patients with localized disease. Additionally, higher T stage and larger tumor were associated with a higher NLR. 81 Therefore, tumor volume might reflect NLR.
In addition to those studies reported in Table 7 , there are two interesting studies. For example, Viers et al. investigated the association between preoperative NLR value and pathological outcome in 2019 patients who underwent radical or partial nephrectomy for localized renal tumors. 105 They showed that patients with benign renal masses had a significantly lower NLR than did those with malignant tumors (median 2.92 vs 3.12, P = 0.037), and that an elevated NLR was associated with high-grade tumor and more aggressive histological subtypes, such as collecting duct carcinoma, at the time of nephrectomy. However, another study by Nayan et al. that analyzed the association among renal biopsy results of a small renal mass, NLR and PLR showed that neither NLR nor PLR differed between benign and primary renal malignant masses. 106 As shown in the studies evaluating CRP level, there have been several studies regarding changes in NLR after treatment. For instance, Park et al. showed that a lower post-treatment NLR and larger reduction in NLR after sunitinib treatment was significantly associated with better response in patients with metastatic ccRCC. 96 Furthermore, post-treatment NLR was a significant prognostic factor of CSS. Another study of post-treatment changes in NLR was carried out by Chang et al. 104 They analyzed the association among preoperative NLR, postoperative change in NLR and survival in patients who underwent radiofrequency ablation for localized RCC. They showed that elevated preoperative NLR ≥2.79 and a change of NLR ≥0.4 were significantly associated with poor DFS; in particular, patients with both factors had the worst DFS. However, the reduction in NLR after treatment in the two studies differed; therefore, further studies are required to clarify the significance of the reduction of NLR after treatment in patients with RCC.
NLR in UC
A summary of 24 recent studies investigating the prognostic role of NLR in RCC according to treatment type is shown in Tables 8-11. 84-87,107-127 Table 8 summarizes studies investigating the prognostic role of preoperative NLR in patients who underwent transurethral resection for NMIBC. The cutoff value for high versus low NLR in those studies varied from 2.2 to 3. The outcomes of the studies were RFS, PFS and OS. All studies showed that increased NLR was associated with worse outcome. Table 9 shows nine studies examining patients who underwent cystectomy for bladder cancer. The cut-off value for high versus low NLR in these studies varied from 2.38 to 3. The outcomes of the studies included RFS, CSS and OS. Two studies evaluated the predictive value of preoperative NLR for extravesical extension. Increased NLR was associated with extravesical extension and poor survival. Table 10 shows six studies examining patients who underwent RNU for with upper tract urothelial cancer. The cut-off value for high versus low NLR in those studies varied from 2.5 to 3.8. The outcomes of the study included RFS, CSS and OS in five studies, and intravesical recurrence in one study. Kishimoto et al. reported that patients with preoperative NLR >3.8 had a higher risk of intravesical recurrence after nephroureterectomy. 119 Table 11 shows five studies evaluating the prognostic value of NLR in patients who received chemotherapy for metastatic UC. Four studies used a cut-off value for NLR of 3, and one study used a value of 3.2. Four studies evaluated the prognostic value of pretreatment NLR, and one study by Rossi et al. evaluated pre-and post-treatment NLR in relation to PFS and OS. Rossi et al. analyzed 292 patients treated with first-line chemotherapy for unresectable or metastatic UC. 127 NLR was measured at pretreatment and at day 1 of the second and third cycles (follow-up NLR). The proportion of patients with NLR >3 before treatment, and at the beginning of the second and third cycles were 67.8%, 23.3% and 21.2%, respectively. The median PFS and OS of patients with follow-up NLR >3 was significantly shorter than that of patients with a follow-up NLR ≤3 (PFS 3.2 months vs 6.9 months, P < 0.0001; OS 5.7 months vs 13.1 months, P < 0.0001). The authors concluded that a persistently increased NLR during chemotherapy is an independent predictive factor for patients with advanced UC. Similarly, Seah et al. showed that a sustained decrease in NLR during neoadjuvant chemotherapy is associated with pathological response in cystectomy specimens from patients with MIBC. 128 Thus, follow up of NLR during chemotherapy might provide additional information in therapeutic monitoring and decision-making regarding treatment change.
NLR in PC
A summary of 15 recent studies investigating the prognostic role of NLR in PC is shown in Table 12 . 76, 88, [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] Six studies investigated the prognostic value of NLR in patients who underwent radical prostatectomy for PC; five studies evaluated the preoperative value, and the remaining studies evaluated postoperative values. The outcomes of those studies included survival (BCRFS, CSS and OS), as well as pathological results. The cut-off value for high versus low NLR varied from 1.76 to 3.5. As for BCRFS, one of the five studies investigated preoperative NLR, and the study investigating postoperative NLR showed increased NLR is significantly associated with biochemical recurrence (P = 0.044 and P = 0.008, respectively). As for pathological results, high preoperative NLR is associated with higher pathological stage, extracapsular extension and lymph node involvement. 132, 133 Seven studies analyzed the association between NLR and survival in patients with mCRPC who received docetaxel chemotherapy. The cut-off value for high versus low NLR varied from 3 to 5. Six studies showed that high pretreatment NLR was associated with poor survival in patients who received docetaxel chemotherapy for mCRPC. 88, [135] [136] [137] [138] [139] In addition to the role of pretreatment NLR, Lorente et al. investigated the prognostic role of changes in NLR with treatment. 138 They showed that 151 (44%) of 345 patients showed conversion from high (≥3) to low (<3) NLR in response to treatment, and that these patients showed better survival than patients with no conversion (median OS, 14.5 months vs 11.7 months, P = 0.032). Lolli et al. analyzed the association of baseline NLR and change in NLR at 4 weeks after treatment with survival in patients who received abiraterone treatment for mCRPC. 140 High baseline NLR was significantly associated with shorter OS (P < 0.001). Based on a combination of baseline NLR and change in NLR at 4 weeks, the patients were classified into four groups: low (<3)-low (<3), low (<3)-high (≥3), high (≥3)-low (<3) and high (≥3)-high (≥3). The high-high and high-low groups showed a significantly worse OS than did the lowlow group. However, the HR was higher in the high-low group than that in the high-high group. Similar to the analysis by Lolli et al., Conteduca et al. investigated the prognostic value of change in NLR in patients with mCRPC who received enzalutamide treatment, and showed that the high-high and high-low groups showed a significantly worse OS than did the low-low group. 141 As Lorente et al. reported, the high-low group seems to have a better prognosis than did the high-high group. Therefore, changes in NLR after medical treatment might provide additional information in therapeutic monitoring and decision-making regarding treatment change in patients with mCRPC. 
PLR
The PLR is defined as the absolute platelet count divided by the absolute lymphocyte count. The PLR, as well as the NLR, is an inexpensive and easily acquired marker that can be used after a routine preoperative blood examination. Table 13 summarizes the results of recent reports evaluating the prognostic value of PLR. 35, 43, 108, 115, [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] The cutoff value for high versus low PLR varied from 117.46 to 218. Higher PLR was significantly associated with poor prognosis in five of 14 studies. The primary sites of cancer reported are kidney in four studies, UUT in three studies, urinary bladder in five studies and prostate in two studies. Three of four studies subjected to kidney cancer, and all five studies subjected to bladder cancer failed to show the prognostic value of PLR. Therefore, further studies are required to clarify the prognostic value of PLR in urological cancer.
Combination markers of serum proteins and differential blood cells
There have been several studies that evaluated the prognostic value of combination markers of serum proteins and differential blood cell counts, such as PNI, which is based on peripheral blood lymphocyte count and serum albumin level; the combination of CRP and NLR; fibrinogen-PLR score, which is based on plasma fibrinogen level and PLR; and fibrinogen-NLR score, which is based on plasma fibrinogen level and NLR. 23, [152] [153] [154] Among these combination markers, the PNI is most widely studied in urological cancer.
PNI in urological cancers
PNI has been introduced as a simple and easily measurable biomarker representing the nutritional and immunological status of cancer patients. Since the first report by Onodera et al., many research groups have investigated the prognostic role of PNI in various types of cancers. 23, [155] [156] [157] The PNI is calculated using the following formula: 10 9 serum albumin value (g/dL) + 0.005 9 peripheral blood lymphocyte count. Therefore, elevated PNI is associated with a good prognosis in cancer patients. However, there are still not many studies evaluating the prognostic value of PNI in patients with urological cancers. Table 14 summarizes the results of recent reports evaluating the prognostic value of PNI. [158] [159] [160] [161] [162] [163] [164] [165] [166] The primary sites of cancer reported were kidney in five studies, UUT in one study, urinary bladder in one study and prostate in one study. The cut-off value for high versus low PNI varied from 41 to 51. Lower PNI was significantly associated with poor prognosis in each study. Two studies evaluated post-treatment changes in PNI. Fan et al. analyzed changes in PNI in patients who received abiraterone treatment for mCRPC. PNI elevation during the first month of abiraterone treatment was significantly associated with the initial response. 166 Furthermore, Kang et al. analyzed PNI dynamics in patients who underwent radical nephrectomy for RCC. 158 The patients were classified into four groups according to PNI dynamics as follows: low (≤45)-low (≤45), low (≤45)-high (>45), high (>45)-low (≤45) and high (>45)-high (>45). Postoperative PNI was measured at 6 months postnephrectomy. Patients with high-high PNI showed the best prognosis. 
Conclusion
In the present review, I provided a concise overview of data from studies regarding SIR markers in urological cancers, specifically CRP, GPS/mGPS, NLR and PNI. The advantages of SIR markers are that they are easily measurable and inexpensive in the clinical setting. However, except for GPS/ mGPS, there has not been a clear cut-off value for other SIR markers, such as NLR and PLR. Among studies investigating the same cancer type, similar disease stage and treatment, cut-off values did not differ widely between studies. In addition, some studies developed a nomogram to predict prognosis, whereas others developed a risk stratification model. Many meta-analyses have already shown the prognostic value of SIR markers in urological cancers. Therefore, it is important to consider how clinicians use these markers in clinical trials and clinical practice.
Many research groups showed that elevated CRP and NLR are associated with worse outcome in patients who were treated with molecular-targeted agents for metastatic RCC or in patients who were treated with docetaxel for mCRPC. However, it is not easy to use CRP or NLR for appropriate drug selection because SIR markers are non-specific. Accordingly, companion diagnostics might become more common in the urological cancer field; for example, detection of PD-L1 protein in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue is essential for treatment with pembrolizumab in patients with non-small cell lung cancer. 167 As suggested by Rossi et al. and Seah et al., follow up using SIR markers after treatment might be one of the ways that SIR markers can be used in clinical practice for therapeutic monitoring and decision-making regarding appropriate timing for changes in medication. 127, 128 Further studies assessing changes of SIR markers over time would be expected.
